Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
FDA grants emergency approval to Pfizer's COVID-19 vaccine for use in children 5- to 11-year old and approves Lilly's (LLY) novel diabetes treatment, Mounjaro (tirzepatide).
Carlisle Companies (NYSE: CSL), Innovative Industrial Properties (NYSE: IIPR) and AbbVie (NYSE: ABBV) have all seen shares double over the past three years. All three have the potential to double their shares again over the next three years because of their stability, consistent revenue growth, and attractive dividends. Carlisle Companies was trading at $105.07 a little more than two years ago.